<div id="readability-page-1"><p><span>Doximity (NYSE:DOCS - Get Free Report)</span> had its price target dropped by analysts at Needham &amp; Company LLC  from $55.00 to $27.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a &#34;buy&#34; rating on the stock. Needham &amp; Company LLC's price objective suggests a potential upside of 14.82% from the company's current price.</p><ul><li>Doximity is the Facebook and LinkedIn of the Medical Community</li></ul><p>Several other equities research analysts have also issued reports on DOCS. BTIG Research lowered Doximity from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a report on Thursday. JPMorgan Chase &amp; Co. reduced their target price on Doximity from $40.00 to $33.00 and set a &#34;neutral&#34; rating for the company in a report on Friday, February 20th. Royal Bank Of Canada  restated an &#34;outperform&#34; rating and issued a $44.00 target price on shares of Doximity in a report on Monday, March 9th. Canaccord Genuity Group  set a $34.00 price target on Doximity and gave the stock a &#34;buy&#34; rating in a report on Monday, February 9th. Finally, BMO Capital Markets  set a $25.00 price target on Doximity in a report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned  a Buy rating and twelve have assigned  a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $33.60.</p><p><b>Read Our Latest Report on DOCS</b></p><h2>Doximity Trading Down 11.1%</h2><ul><li>Doximity is an Overlooked Medical Ecosystem AI Play </li></ul><p>Shares of Doximity stock opened at $23.52 on Thursday. The firm has a market cap of $4.34 billion, a price-to-earnings ratio of 19.60, a price-to-earnings-growth ratio of 1.88 and a beta of 1.36. Doximity has a 52-week low of $20.55 and a 52-week high of $76.51. The firm's 50-day moving average price is $24.27. </p><p>Doximity announced that its board has initiated a share repurchase plan on Thursday, February 5th that permits the company to buyback $500.00 million in  outstanding  shares. This buyback authorization permits the company to purchase up to 8% of its stock  through open market purchases. Stock  buyback plans are typically an indication that the company's management believes its stock is undervalued. </p><h2>Insider Buying and Selling</h2><ul><li>Doximity Stock is an Interesting Healthcare Play</li></ul><p>In other news, Director Kira Scherer Wampler sold 9,000 shares of the business's stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $26.06, for a total transaction of $234,540.00. Following the sale, the director directly owned 19,839 shares in the company, valued at approximately $517,004.34. The trade was a 31.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Siddharth Sitaram sold 2,309 shares of the business's stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $25.77, for a total value of $59,502.93. Following the sale, the insider owned 89,396 shares in the company, valued at approximately $2,303,734.92. This represents a 2.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 18,055 shares of company stock worth $456,061. 31.30% of the stock is currently owned by company insiders. </p><h2>Institutional Investors Weigh In On Doximity</h2><p>A number of hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in  Doximity by 4.1% in the fourth quarter. Vanguard Group Inc. now owns 13,285,485 shares of the company's stock valued at $588,281,000 after acquiring an additional 518,916 shares during the last quarter.  Aubrey Capital Management Ltd bought a new position in  Doximity in the third quarter valued at about $4,572,000.  UBS Group AG lifted its stake in  Doximity by 26.5% in the fourth quarter. UBS Group AG now owns 680,260 shares of the company's stock valued at $30,122,000 after buying an additional 142,408 shares during the period.  Blair William &amp; Co. IL lifted its stake in  Doximity by 1,990.7% in the third quarter. Blair William &amp; Co. IL now owns 362,740 shares of the company's stock valued at $26,534,000 after buying an additional 345,390 shares during the period.  Finally, William Blair Investment Management LLC lifted its stake in  Doximity by 11.7% in the third quarter. William Blair Investment Management LLC now owns 5,829,169 shares of the company's stock valued at $426,404,000 after buying an additional 609,775 shares during the period. Institutional investors and hedge funds own  87.19% of the company's stock. </p><h2>Key Headlines Impacting Doximity</h2><p>Here are the key news stories impacting Doximity this week:</p><ul>   <li><span>Positive Sentiment: </span>Doximity reported adjusted earnings of $0.26 per share, beating the lower analyst estimate of $0.17, and revenue rose 5.1% year over year to $145.37 million, showing the business is still growing. <i></i><span>Doximity Earnings Report</span></li>   <li><span>Neutral Sentiment: </span>The company’s high margin profile remained intact, with a 23.84% return on equity and 37.54% net margin, suggesting continued operational efficiency. <i></i><span>Fiscal Q4 Earnings Snapshot</span></li>   <li><span>Negative Sentiment: </span>Despite the earnings beat versus one estimate, Doximity missed the broader Zacks consensus of $0.28 per share, which may have disappointed traders looking for a stronger beat. <i></i><span>Doximity Lags Q4 Earnings Estimates</span></li>   <li><span>Negative Sentiment: </span>More importantly for investors, Doximity’s first-quarter FY2027 revenue guidance of $151 million to $152 million came in below the $153.2 million consensus, and full-year FY2027 revenue guidance of $664 million to $676 million also missed the $696 million estimate, signaling a softer outlook. <i></i><span>Doximity Q4 2026 Earnings Call Transcript</span></li>   <li><span>Negative Sentiment: </span>The stock also faced added caution from an insider sale earlier in the week, though it was disclosed as part of a pre-arranged 10b5-1 plan and tax withholding related to equity vesting. <i></i><span>Insider Trade Disclosure</span></li> </ul><h2>About Doximity</h2> (Get Free Report)<p>Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers. </p><p>The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.</p><h2>Read More</h2><ul><li>Five stocks we like better than Doximity</li><li>Airplane Maintenance Companies That Keep Flights Moving Are Ready to Soar</li><li>Oklo Stock Could Be Ready for Another Massive Run</li><li>D-Wave Earnings Looked Weak, But Investors May Be Missing This</li><li>Nebius Upside Expands as AI Feedback Loop Intensifies</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURPQ1M?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURPQ1M"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Doximity Right Now?</h2><p>Before you consider Doximity, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.</p><p>While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

DOCS

LGHT

HEAL

<p>Needham & Company LLC has lowered its price target for Doximity (NYSE:DOCS) from $55.00 to $27.00 while maintaining a "buy" rating. This suggests a potential upside of 14.82% from the current price. Other analysts have also adjusted their ratings, with BTIG Research downgrading to "neutral" and JPMorgan reducing their target to $33.00. Doximity's stock opened at $23.52, with a market cap of $4.34 billion. The company has initiated a $500 million share repurchase plan, indicating management's belief in the stock's undervaluation.</p>

Market Beat

Doximity

Langar Global HealthTech ETF

Global X HealthTech ETF

JPMorgan Chase

ROYAL BANK OF CANADA

Bank of Montreal

UBS Group AG

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Doximity (NYSE:DOCS) Given New $27.00 Price Target at Needham & Company LLC